Erin Currie

Erin has a BSc in Cell & Molecular Biology and has worked in biomedical research in Canada and the UK. At the University of British Columbia her work focussed on specialised cells in the olfactory system and their ability to stimulate neuronal regeneration following damage to the nervous system; her focus shifted to the regulation of haematopoietic stem cells in normal development and leukaemia at Cancer Research UK in London.

Her recent work includes acting for Eli Lilly in patent revocation proceedings relating to the dosage regimen of its blockbuster tadalafil product in first instance and appeal proceedings. She has subsequently assisted in co-ordinating multi-jurisdictional European litigation alongside completing a Postgraduate Diploma in Intellectual Property Law and Practice at the University of Oxford.